197 related articles for article (PubMed ID: 19896233)
21. Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics.
Fang YM; MacKeen D; Egan JF; Zelop CM
J Matern Fetal Neonatal Med; 2009 Mar; 22(3):249-53. PubMed ID: 19330710
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
Home PD; Fritsche A; Schinzel S; Massi-Benedetti M
Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629
[TBL] [Abstract][Full Text] [Related]
23. Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
Gundgaard J; Christensen TE; Thomsen TL
Prim Care Diabetes; 2010 Oct; 4(3):165-72. PubMed ID: 20452847
[TBL] [Abstract][Full Text] [Related]
24. Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal-bolus regimen.
Christensen TE; Gundgaard J; Pilgaard T
J Med Econ; 2011; 14(4):477-85. PubMed ID: 21668290
[TBL] [Abstract][Full Text] [Related]
25. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
Gschwend MH; Aagren M; Valentine WJ
J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
29. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
30. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
Pawaskar M; Zagar A; Sugihara T; Shi L
J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
[TBL] [Abstract][Full Text] [Related]
31. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
[TBL] [Abstract][Full Text] [Related]
32. Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis.
Anderten H; Dippel FW; Kostev K
J Diabetes Sci Technol; 2015 May; 9(3):644-50. PubMed ID: 25573957
[TBL] [Abstract][Full Text] [Related]
33. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
Rashid N; McCombs JS; Schwartz E
Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
[TBL] [Abstract][Full Text] [Related]
34. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
35. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
36. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
Asche CV; Luo W; Aagren M
Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
[TBL] [Abstract][Full Text] [Related]
37. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes.
Rhoads GG; Dain MP; Zhang Q; Kennedy L
Diabetes Obes Metab; 2011 Aug; 13(8):711-7. PubMed ID: 21410859
[TBL] [Abstract][Full Text] [Related]
38. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
Fabunmi R; Nielsen LL; Quimbo R; Schroeder B; Misurski D; Wintle M; Wade R
Curr Med Res Opin; 2009 Mar; 25(3):777-86. PubMed ID: 19203299
[TBL] [Abstract][Full Text] [Related]
39. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
Idris I; Gordon J; Tilling C; Vora J
J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
